FindTrial
Sign In

fluticasone furoate (FF)

DRUG4 trials

Sponsors

GlaxoSmithKline, University of Chicago

Conditions

AsthmaPulmonary Disease, Chronic ObstructiveRhinitis, Allergic, PerennialSeasonal Allergic Rhinitis

Phase 2

To Investigate the Effects of Altering the Time of Day of Dosing (Morning or Evening) With Fluticasone Furoate 100 Micrograms Once Daily Administered Via a Dry Powder Inhaler in Subjects With Asthma
CompletedNCT01808339
GlaxoSmithKlineAsthma
Start: 2013-03-31End: 2014-03-31Updated: 2017-01-09

Phase 3

Fluticasone Nasal Spray Patient Preference Study
CompletedNCT00398476
GlaxoSmithKlineRhinitis, Allergic, Perennial
Start: 2006-12-01End: 2006-12-04Updated: 2018-03-01
A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02164513
GlaxoSmithKlinePulmonary Disease, Chronic Obstructive
Start: 2014-06-30End: 2017-07-17Updated: 2018-10-10

Phase 4

Effect of Veramyst and Olopatadine 0.2% Opthalmic Solution on Allergy Symptoms
CompletedNCT01007253
University of ChicagoSeasonal Allergic Rhinitis
Start: 2009-11-30End: 2011-08-31Updated: 2013-07-17

Related Papers

Implementation of 2023 Canadian Thoracic Society Guidelines for Single-Inhaler Triple Therapy Could Reduce Exacerbation and Mortality Rates in COPD: PROMETHEUS Canada.
2026-03-30
Impact of Increased Single-Inhaler Triple Therapy Use in Appropriate Patients on Chronic Obstructive Pulmonary Disease Exacerbations, Mortality, and Medical Costs: PROMETHEUS Spain.
2025-11-21
Impact of Increased Use of Single-Inhaler Triple Therapies on COPD Exacerbation Rates, Mortality, and Total Costs: PROMETHEUS France.
2025-11-17
Modeled reductions in COPD exacerbation rates, mortality, and related medical costs due to increased SITT adoption: PROMETHEUS Italy.
2025-10-28
Comparison of Individual and Composite Measures to Assess Disease Stability over Time in Patients with COPD Treated with Fluticasone Furoate/Umeclidinium/Vilanterol: A Post Hoc Analysis
American Journal of Respiratory and Critical Care Medicine2025-05-01
The long-term clinical and economic benefits of treating advanced COPD patients with single-inhaler triple therapy in Quebec, Canada - The IMPACT trial.
2024-06-04
Association between Increased Risk of Pneumonia with ICS in COPD: A Continuous Variable Analysis of Patient Factors from the IMPACT Study
Pulmonary Therapy2024-03-066 citations
Late Breaking Abstract - ECG-derived risk factors for adverse cardiopulmonary outcomes in COPD patients: IMPACT post hoc analysis
2023-09-091 citations
Heterogeneous treatment effect estimation of LABA/LAMA/ICS on COPD exacerbation risk in the IMPACT trial
2023-09-09
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.
2023-08-297 citations
Estimating individual treatment effects on COPD exacerbations by causal machine learning on randomised controlled trials
Thorax2023-04-0317 citations
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
2022-11-117 citations
Time‐Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial
Journal of the American Heart Association2022-09-1472 citations
Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial.
2022-07-252 citations
Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT Trial
Chronic Obstructive Pulmonary Diseases Journal of the COPD Foundation2021-12-2312 citations
Predicting SGRQ score based on CAT score: post-hoc analysis of the IMPACT trial
2021-09-051 citations
IMPACT: Healthcare resource use data and associated costs for single-inhaler triple therapy versus dual therapies in Spain
2021-09-051 citations
Cost-effectiveness of single-inhaler triple therapy for chronic obstructive pulmonary disease treatment by baseline blood eosinophil count: IMPACT trial
2021-09-05
InforMing the PAthway of COPD Treatment (IMPACT) trial: fibrinogen levels predict risk of moderate or severe exacerbations.
2021-04-2817 citations
Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial.
2020-12-073 citations

26 more papers not shown